BCG Vaccine Market

Market Overview

The global BCG Vaccine Market size was valued at USD 50.5 million in 2021 and is predicted to reach USD 76.3 million by 2030 at a CAGR of 4.7% from 2022 to 2030. BCG vaccine, also known as Bacille Calmette-Guérin, is a vaccine used against tuberculosis (TB) or leprosy disease. It is made from a weaker version of the bacterium called Mycobacterium bovis, which is similar to the bacteria that causes TB.

The BCG vaccine does not require the use of a needle and syringe; instead, the vaccine is administered as a liquid applied directly to the skin or the upper arm. The vaccine is immediately delivered into the superficial layers of the skin by using a multi-pronged needle system that pricks the skin through the liquid.

The vaccine offers immunity and safety to counter tuberculosis (TB). It can also prevent other infections such as Buruli ulcer infection and others. BCG is given to children at birth and adults under the age of 35 who are at risk of contracting tuberculosis, mycobacteria, and cancer.

Market Dynamics and Trends

The demand for the BCG vaccine is high due to surging cases of tuberculosis because of unhealthy diets and malnutrition worldwide. According to WHO, in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. Of these, 5.6 million were men, 3.3 million were women, and 1.1 million were children.

Also, the prevalence of bladder cancer has boosted the market growth of BCG vaccine, as it is used for the treatment of bladder cancer and tumor. Moreover, the surge in the number of newborn babies boosts the market growth, as TB is a fatal infection that can cause TB meningitis and even mortality in babies.

Furthermore, the launch of awareness programs by international organizations, such as UNICEF and WHO, to envision a TB-free world is expected to propel the market growth during the forecast period. For instance, WHO declared March 24 as World Tuberculosis (TB) Day to raise public awareness regarding the use of BCG vaccine to combat TB. This initiative created awareness about TB’s devastating health, social, and economic consequences. Moreover, in March 2022, World TB Day and TB Alliance joined hands around the globe to raise awareness and take proactive steps to make a TB-free world.

However, the side effects of the BCG vaccine, such as swollen head glands and high temperature, hamper the market growth. On the contrary, BCG vaccine is the only vaccine available for treating tuberculosis globally, which is expected to create ample growth opportunities for the market in the coming years.

Market Segmentations and Scope of the Study

The BCG vaccine market is segmented based on type, demographics, application, distribution channel, and geography. On the basis of type, the market is divided into immune BCG and therapy BCG. On the basis of demographics, the market is categorized into pediatrics and adults. On the basis of usage, the market is bifurcated into tuberculosis and bladder cancer. On the basis of end-user, the market is categorized into hospitals, clinics, and others. The report contains the geographical breakdown and analysis of each of the abovementioned segments across four regions, namely North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Geographical Analysis

Asia-Pacific currently holds the predominant share of the BCG vaccine market. It is expected to continue its dominance during the forecast period due to the rising birth rate in the region and the increasing prevalence of tuberculosis, especially in newborn babies owing to malnutrition in pregnant women. Furthermore, excessive tobacco use across the region drives the market’s growth, as tobacco consumption can damage the lungs, leading to severe lung infection.

For instance, according to Tobacco Tactics, in November 2021, the highest prevalence of tobacco was reported in the South East Asian Region (SEAR), which includes 11 countries, namely India, Bangladesh, Indonesia, Nepal, Sri Lanka, and others. The average prevalence of tobacco consumption among males was reported to be about 46%, while it was 9.7% among females in this region.

In addition, government initiatives in countries such as India and South Korea are expected to drive the BCG vaccine market growth in the region. For instance, in March 2022, The Serum Institute requested the Drugs Controller General of India to authorize its recombinant BCG vaccine to prevent tuberculosis in the region. Currently, India’s TB immunization program offers BCG vaccination at birth or as early as possible until the age of one year.

Also, in March 2021, the TB Alliance, along with the support of South Korea, announced an initiative known as LIFT-TB (Leveraging Innovation for Faster Treatment of Tuberculosis) to broaden the adoption and scale-up of new TB treatment regimens. The initiative seeks to increase the completion of TB treatment rates in some countries most affected by TB across the Southeast and Central Asian regions, including Indonesia, Myanmar, Philippines, Vietnam, Kyrgyzstan, Ukraine, and Uzbekistan.

On the other hand, the market in North America is expected to show steady growth due to the high consumption rate of cigarettes in the region that damage the lungs and can cause tuberculosis or other lung infection. For instance, according to the Centers for Disease Control and Prevention, in 2020, an estimated 30.8 million adults in the U.S. smoke cigarettes, resulting in more than 16 million Americans living with a smoking-related disease.

Also, a surge in the cases of bladder cancer in the region has spiked the growth of the BCG vaccine market. For instance, the Centers for Disease Control and Prevention announced that in the U.S. about 18,000 women and 57,000 men suffer from bladder cancer every year. Moreover, every year nearly about 16,700 people die from this disease in the U.S.  

Competitive Landscape

The key players in the BCG vaccine market include Sanofi Pasteur, Merck & Co., Inc., China National Biotec Group, Japan BCG Laboratory, InterVax Ltd., Serum Institute of India Pvt. Ltd., Biofabri, GreenSignal Bio Pharma Limited (GSBPL), AJ Biologics, and Torlak Institute of Virology. These market players have adopted various strategies, such as partnerships and product launches, across various regions to maintain their dominance in the BCG vaccine market.

For instance, in May 2022, Serum Institute of India Pvt. Ltd. received the market authorization for Cy TB kit from the drug regulator, DCGI. The kit will be used as a skin test for diagnosing latent tuberculosis, which is expected to increase the demand for TB vaccine in the market.

In July 2021, Biofabri and IAVI announced a partnership on efficacy trials of a TB vaccine known as MTBVAC. This agreement will provide a step forward to advance TB vaccine development, primarily focusing on low and middle-income countries.

Key Benefits

• The BCG vaccine market report provides a quantitative analysis of the current market and estimations from 2022 to 2030 that assists in identifying and capitalizing on the prevailing market opportunities.

• The study comprises a deep dive analysis of the BCG vaccine market trend, including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints, and opportunities and their impacts on the BCG vaccine market is provided in the report.

• The competitive analysis of the market players, along with their market shares, is included in the study.

• The SWOT analysis and Porter’s Five Forces model are elucidated in the report.

• The report includes the value chain analysis of the market to provide a clear picture of the stakeholders’ roles.

Key Market Segments

By Type

• Immune BCG

• Therapy BCG

By Demographics

• Pediatrics (0-18 Years)

• Adults (19-35 Years)

By Application

• Tuberculosis

• Bladder Cancer

By Distribution Channel

• Hospitals

• Clinics

• Others

By Geography

• North America

  • U.S

  • Canada

  • Mexico

• Europe

  • UK        

  • Germany        

  • France        

  • Spain        

  • Italy        

  • Netherlands        

  • Denmark        

  • Finland        

  • Norway        

  • Sweden        

  • Russia        

  • Rest of Europe

• Asia-Pacific

  • China        

  • Japan        

  • India

  • Australia

  • South Korea    

  • Thailand    

  • Singapore

  • Rest of Asia-Pacific    

• RoW

  • Latin America

  • Middle East        

  • Africa

Key Players

• Sanofi Pasteur

• Merck & Co., Inc.

• China National Biotec Group

• Japan BCG Laboratory

• InterVax Ltd.

• Serum Institute of India Pvt. Ltd.

• Biofabri

• GreenSignal Bio Pharma Limited

•  AJ Biologics

• Torlak Institute of Virology

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2021–2030
Base Year Considered	2021
Forecast Period	2022–2030
Market Size Estimation	Million (USD)
Market Segmentation	By Type (Immune BCG, Therapy BCG), By Demographics (Pediatrics (0-18 Years), Adults (19-35 Years)), By Application (Tuberculosis, Bladder Cancer), By Distribution Channel (Hospitals, Clinics, Others)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Germany, France, Spain, Italy, Netherlands, Denmark, Finland, Norway, Sweden, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Thailand, Singapore, Rest of Asia-Pacific), Rest of the World (Latin America, Middle East, Africa)
Companies Profiled	Sanofi Pasteur, Merck & Co., Inc., China National Biotec Group, Japan BCG Laboratory, InterVax Ltd., Serum Institute of India Pvt. Ltd., Biofabri, GreenSignal Bio Pharma Limited (GSBPL), AJ Biologics, and Torlak Institute of Virology.